Literature DB >> 3709653

Differential effects of cimetidine and ranitidine on imipramine demethylation and desmethylimipramine hydroxylation by human liver microsomes.

E Spina, Y Koike.   

Abstract

The effect of cimetidine and ranitidine on the demethylation of imipramine (IMI) and on the hydroxylation of desmethylimipramine (DMI) was studied in microsomes from four human livers. Cimetidine inhibited both demethylation of IMI and 2-hydroxylation of DMI, whilst the effect of ranitidine was not statistically significant. 2-hydroxylation of DMI is probably mediated by debrisoquine hydroxylase, a cytochrome P-450 isozyme that is monogenically controlled. The results suggest that cimetidine inhibits this enzyme.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3709653     DOI： 10.1007/bf00614311

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  18 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

2.  High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites.

Authors:  T A Sutfin; W J Jusko
Journal:  J Pharm Sci       Date:  1979-06       Impact factor: 3.534

Review 3.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 4.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

5.  E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Authors:  B Mellström; L Bertilsson; J Säwe; H U Schulz; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Cimetidine interaction with imipramine and nortriptyline.

Authors:  S A Henauer; L E Hollister
Journal:  Clin Pharmacol Ther       Date:  1984-02       Impact factor: 6.875

7.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.

Authors:  E Spina; C Birgersson; C von Bahr; O Ericsson; B Mellström; E Steiner; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

8.  Cimetidine's effect on steady-state serum nortriptyline concentrations.

Authors:  D D Miller; J B Sawyer; J P Duffy
Journal:  Drug Intell Clin Pharm       Date:  1983-12

9.  Desmethylimipramine overdose: nonlinear kinetics in a slow hydroxylator.

Authors:  E Spina; T K Henthorn; L Eleborg; C Nordin; J Säwe
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

10.  Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism.

Authors:  D A Henry; I A Macdonald; G Kitchingman; G D Bell; M J Langman
Journal:  Br Med J       Date:  1980-09-20
View more
  4 in total

Review 1.  Side effects of ranitidine.

Authors:  T Vial; C Goubier; A Bergeret; F Cabrera; J C Evreux; J Descotes
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 2.  Clinical pharmacokinetics of imipramine and desipramine.

Authors:  F R Sallee; B G Pollock
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

3.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Authors:  D Wu; S V Otton; B A Sproule; U Busto; T Inaba; W Kalow; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.